Description

TroDelvy 200mg Injection (Sacituzumab Govitecan) Uses, Dosage, Side Effects & Price in Pakistan

TroDelvy 200mg Injection (Sacituzumab Govitecan) is a prescription cancer medicine containing sacituzumab govitecan as its active ingredient. It is an antibody-drug conjugate used to treat certain types of advanced or metastatic breast cancer.

TroDelvy is used as a targeted treatment for certain adults with triple-negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative breast cancer, depending on the patient’s previous treatments and disease status. Current European product information also includes a newer treatment setting involving pembrolizumab for certain previously untreated metastatic or locally advanced TNBC patients whose tumours express PD-L1.

TroDelvy is supplied as a 200mg powder in a vial and must be prepared and administered as an intravenous (IV) infusion by a qualified healthcare professional. It is not intended for self-injection.

What Is TroDelvy 200mg Injection?

TroDelvy contains sacituzumab govitecan, an antibody-drug conjugate used in cancer treatment.

The medicine combines an antibody that targets Trop-2, a protein found on many cancer cells, with SN-38, an active component related to irinotecan. The antibody helps deliver the drug to Trop-2-expressing cells, where SN-38 interferes with topoisomerase I, an enzyme needed for DNA replication. This can prevent cancer cells from multiplying and lead to their death.

Each vial contains 200mg of sacituzumab govitecan as a powder for concentrate for solution for infusion. After reconstitution, the concentration is 10mg/mL.

TroDelvy 200mg Injection Uses

The approved use of TroDelvy can vary depending on the country and the patient’s previous cancer treatments.

Triple-Negative Breast Cancer

TroDelvy is used for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer.

The European indication includes patients who have received two or more prior systemic therapies, including at least one treatment for advanced disease. Current European information also includes Trodelvy in combination with pembrolizumab for certain patients with previously untreated unresectable locally advanced or metastatic TNBC whose tumours express PD-L1 with a CPS of at least 10.

Hormone Receptor-Positive, HER2-Negative Breast Cancer

TroDelvy is also indicated in Europe as monotherapy for adults with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the advanced setting.

Because cancer-medicine approvals can differ between countries, patients should follow their oncologist’s recommendation and the official product information applicable to their medicine.

How Does TroDelvy 200mg injection (Sacituzumab Govitecan) Work?

TroDelvy is an antibody-drug conjugate (ADC).

Its antibody component recognises Trop-2 on cancer cells. After binding to the cell, the medicine is taken inside the cell and releases SN-38.

SN-38 inhibits topoisomerase I, an enzyme involved in copying DNA. By interfering with this process, TroDelvy can prevent susceptible cancer cells from multiplying and can ultimately cause cancer-cell death.

TroDelvy 200mg Injection Dosage

For the approved breast cancer indications, the recommended dose of TroDelvy is generally 10mg/kg, administered by intravenous infusion on Day 1 and Day 8 of a 21-day treatment cycle. Treatment can continue as long as the medicine remains effective and side effects remain acceptable.

The exact dose is calculated according to the patient’s body weight and may be modified by the oncologist because of side effects or other medical factors.

TroDelvy should not be self-administered. Dose calculations, preparation, dilution and infusion must be performed by trained healthcare professionals.

How Is TroDelvy 200mg Injection Given?

TroDelvy is administered through an intravenous infusion.

The powder in the vial must first be reconstituted and diluted according to the official preparation instructions. The infusion is then administered by a healthcare professional.

Patients are monitored during the infusion and for at least 30 minutes after the infusion because infusion-related reactions can occur. Medicines may be given before treatment to reduce the risk of infusion reactions.

TroDelvy should only be administered in a healthcare setting where appropriate medical support is available.

TroDelvy 200mg Side Effects

Like other anticancer medicines, TroDelvy can cause side effects.

Commonly reported side effects include:

• Low neutrophil count (neutropenia)
• Nausea
• Diarrhea
• Tiredness
• Hair loss
• Anemia
• Constipation
• Vomiting
• Reduced appetite

Some side effects can be serious and require prompt medical attention.

Neutropenia

TroDelvy can cause severe neutropenia, which means a significant reduction in neutrophils, a type of white blood cell that helps fight infections.

The FDA prescribing information carries a boxed warning for severe, life-threatening or fatal neutropenia. Blood counts should therefore be monitored during treatment.

Patients should promptly report fever, chills or other signs of infection to their healthcare team.

Diarrhea

Diarrhea is another important side effect associated with TroDelvy. Severe diarrhea can result in dehydration and may require medical treatment.

The FDA recommends monitoring patients with diarrhea and providing appropriate fluids and electrolytes when necessary.

Infusion-Related Reactions

Infusion-related reactions, including serious hypersensitivity reactions, can occur.

Patients are monitored during the infusion and afterwards. If a significant reaction develops, the healthcare professional may slow or stop the infusion and provide appropriate treatment.

TroDelvy Precautions and Warnings

Before receiving TroDelvy, tell your doctor about your complete medical history and all medicines you are using.

Important precautions include:

• Low blood counts: TroDelvy can cause neutropenia and anemia.
• Infections: Severe neutropenia can increase the risk of serious infection.
• Diarrhea: Severe diarrhea requires prompt assessment and treatment.
• Infusion reactions: Patients should be monitored during and after infusion.
• Allergic reactions: Tell your doctor about previous severe reactions to medicines.
• Liver problems: Your healthcare team may monitor liver function where appropriate.
• Pregnancy: TroDelvy may harm an unborn baby.
• Breastfeeding: Breastfeeding is not recommended during treatment.

Your oncologist may perform regular blood tests to monitor blood-cell counts and assess whether treatment should continue or the dose should be modified.

TroDelvy Drug Interactions

Tell your doctor about every medicine, supplement and herbal product you use.

Sacituzumab govitecan contains the active metabolite SN-38, which is metabolised by UGT1A1. Medicines or genetic factors that reduce UGT1A1 activity may affect exposure to SN-38.

Patients with reduced UGT1A1 activity may have an increased risk of certain adverse effects, particularly neutropenia.

Your oncology team should review your medication list before treatment and during therapy to identify clinically relevant interactions.

TroDelvy Pregnancy and Breastfeeding

TroDelvy may cause harm to an unborn baby. Women who can become pregnant should discuss effective contraception with their healthcare provider before starting treatment.

If pregnancy occurs during treatment, inform the treating doctor promptly.

Breastfeeding is generally not recommended during TroDelvy treatment. Patients should follow their oncologist’s advice regarding when breastfeeding can safely resume.

TroDelvy 200mg Injection Storage

TroDelvy should be stored by healthcare professionals according to the official product information.

The EMA product information states that unopened TroDelvy vials should be stored in a refrigerator at 2°C–8°C and should not be frozen. The vial should remain in its outer carton to protect it from light.

After reconstitution and dilution, the prepared infusion solution has specific storage requirements and should be handled according to the official preparation instructions.

TroDelvy is a cytotoxic medicine, so appropriate handling and disposal procedures must be followed.

TroDelvy 200mg Injection Manufacturer

According to the current EMA product information, the Marketing Authorisation Holder and manufacturer is Gilead Sciences Ireland UC, Carrigtohill, County Cork, Ireland.

When purchasing an imported medicine, always check the actual vial and carton for the manufacturer, batch number, expiry date, strength and packaging condition.

TroDelvy 200mg Price in Pakistan

The TroDelvy 200mg Injection Price in Pakistan can vary depending on supplier, availability, import status, exchange rates and stock conditions.

Because TroDelvy is a specialized oncology medicine, its price may change depending on the source and availability.

Before purchasing, confirm the exact:

• Product name
• 200mg strength
• Pack size
• Manufacturer
• Batch number
• Expiry date
• Packaging condition

Customers can contact Impo Medic to check the current TroDelvy 200mg price and availability in Pakistan.

Buy TroDelvy 200mg Injection in Pakistan

If you want to Buy TroDelvy 200mg Injection in Pakistan, you can contact Impo Medic to confirm current availability, pricing and ordering information.

TroDelvy is a prescription oncology medicine and must be administered by a qualified healthcare professional. It should not be self-injected or used without an oncologist’s prescription.

For imported cancer medicines, customers should verify the product strength, manufacturer, expiry date and packaging before accepting the medicine.

Why Choose Impo Medic?

Impo Medic helps customers in Pakistan find specialized and imported medicines with clear product information and ordering support.

Customers can benefit from:

• Clear medicine and product information
• Convenient online ordering support
• Current availability information
• Transparent pricing where available
• Assistance with imported specialty medicines
• Customer support for product-related queries
• Responsible medicine-use guidance

Availability and pricing can change, particularly for imported oncology medicines, so customers should confirm current information before placing an order.

FAQs About TroDelvy 200mg Injection

1. What is TroDelvy 200mg Injection used for?

TroDelvy contains sacituzumab govitecan and is used for certain adults with advanced or metastatic breast cancer, including specific forms of triple-negative breast cancer and hormone receptor-positive, HER2-negative breast cancer. Approved indications vary by country.

2. What is the active ingredient in TroDelvy?

The active ingredient is sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2.

3. How is TroDelvy 200mg Injection given?

TroDelvy is administered as an intravenous infusion by a qualified healthcare professional. It is given on Day 1 and Day 8 of a 21-day treatment cycle for the approved breast cancer indications.

4. What is the recommended TroDelvy dose?

The usual recommended dose is 10mg/kg once weekly on Days 1 and 8 of each 21-day cycle for the relevant approved indications. The oncologist may modify treatment depending on side effects and the patient’s condition.

5. What are the common TroDelvy side effects?

Common side effects include neutropenia, nausea, diarrhea, tiredness, hair loss, anemia, constipation, vomiting and reduced appetite.

6. Can TroDelvy cause low white blood cells?

Yes. TroDelvy can cause significant neutropenia, which can increase the risk of infection. Blood counts are monitored during treatment.

7. What is the TroDelvy 200mg Price in Pakistan?

The price may vary according to supplier, availability, import costs and stock status. Contact Impo Medic for the current price and availability.

8. Can I Buy TroDelvy 200mg Injection in Pakistan?

You can contact Impo Medic to check current availability, price and delivery information. Because TroDelvy is a prescription cancer medicine, it should only be used and administered under appropriate medical supervision.